Apotex wins tentative FDA approval for generic Ozempic, drug makers await Health Canada decisions

Apotex received tentative FDA approval for a generic version of Ozempic, potentially entering the U.S. market six years before the patent expires there. The news is positive for Apotex and highlights accelerating competition in GLP-1 drugs, though no generic Ozempic has yet been approved in Canada despite legalization three months ago. The main implications are regulatory and competitive rather than broad market-wide.

Analysis

Apotex received tentative FDA approval for a generic version of Ozempic, potentially entering the U.S. market six years before the patent expires there. The news is positive for Apotex and highlights accelerating competition in GLP-1 drugs, though no generic Ozempic has yet been approved in Canada despite legalization three months ago. The main implications are regulatory and competitive rather than broad market-wide.